COLUMBIA, Md., April 19, 2021 /PRNewswire/ -- Advarra, the market leader in regulatory review solutions, research quality, compliance consulting services, and clinical site technologies, today began ...
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of ...
COLUMBIA, Md., Oct. 5, 2021 /PRNewswire/ -- Advarra, the market leader in practice management technology for clinical research and regulatory review solutions, today kicked off Onsemble, the premier ...
Cardiff Oncology Inc (NASDAQ:CRDF) provided a clinical update on the first release of data from its ONSEMBLE trial of onvansertib in combination with FOLFIRI/bev in patients with second-line ...
Next trial in RAS-mutated mCRC (ONSEMBLE) is a randomized Phase 2 trial to demonstrate onvansertib's contribution to SoC and position for a possible accelerated approval opportunity; topline data ...
Cardiff Oncology, Inc. (Nasdaq: crdf ), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, ...
Welcome to the Cardiff Oncology Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. After the speaker's ...
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, ...
MADISON, Wis., April 10, 2012 /PRNewswire/ -- More than 200 clinical research professionals attended the 13th Onsemble conference — a record-breaking attendance in the history of the semi-annual event ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results